WT1 and neoplasm: This being said, the intuitive retrograde approach, based on modulating the expression of WT1 in RCC, is being evaluated in multiple experimental and clinical applications (WT1-targeted vaccination with peptide, mRNA or loaded dendritic cells [40,41]; WT1-targeted cytotoxic T lymphocytes, obtained by using induced pluripotent stem cell technology [42]), which have shown promising initial results in suppressing RCC tumor phenotypes.